LAVA Therapeutics N.V. (LVTX) annual cash flow statement — 6-year operating, investing & financing history
| Cash from Operations | -31.67M | -19.54M | -40.28M | 4.04M | -28.65M | -9.31M | -8.62M |
| Operating CF Margin % | - | -163.11% | -595.11% | 20.85% | -535.46% | -248.39% | - |
| Operating CF Growth % | -1217.91% | 51.48% | -1096.36% | 114.11% | -207.8% | -8.03% | - |
| Net Income | -23.28M | -25.11M | -41.87M | -31.91M | -42.35M | -15.88M | -9.69M |
| Depreciation & Amortization | -102K | 467K | 612K | 781K | 558K | 464K | 259K |
| Stock-Based Compensation | 1.96M | 3.23M | 5.04M | 0 | 0 | 557K | 192K |
| Deferred Taxes | 240K | -10K | 0 | 0 | 0 | -43K | 0 |
| Other Non-Cash Items | -5.22M | -2.5M | -187K | 1.06M | 2.31M | 869K | 0 |
| Working Capital Changes | -5.02M | 4.38M | -3.88M | 34.11M | 10.84M | 4.73M | 621K |
| Change in Receivables | 0 | 0 | 1.59M | -2.48M | 742K | -1.26M | 81K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -1.22M | -1.57M | 352K | 1.41M | 1.62M | 323K | -190K |
| Cash from Investing | 51.34M | 12.47M | -17.64M | 9.35M | -43.55M | -502K | -792K |
| Capital Expenditures | 0 | -23K | -731K | -587K | -764K | -502K | -762K |
| CapEx % of Revenue | 0% | 0.19% | 10.8% | 3.03% | 14.28% | 13.4% | - |
| Acquisitions | 293.92K | 88K | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -11.92K | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | -206K | -569K | 0 | 283K | 151.16M | 18.97M | 1.18M |
| Debt Issued (Net) | -206K | -596K | 0 | 611K | 680K | 1.79M | 1.18M |
| Equity Issued (Net) | 0 | 27K | 0 | 15K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -5.17M | -4.85M | 0 |
| Other Financing | 0 | 0 | 0 | -343K | -340K | 0 | 0 |
| Net Change in Cash | 22.7M | -9.22M | -56.1M | 9.46M | 75.11M | 8.48M | -8.66M |
| Free Cash Flow | -31.67M | -19.57M | -41.01M | 3.46M | -29.41M | -9.81M | -9.38M |
| FCF Margin % | -634.61% | -163.3% | -605.91% | 17.82% | -549.74% | -261.78% | - |
| FCF Growth % | -10.23% | 52.29% | -1286.75% | 111.75% | -199.84% | -4.61% | - |
| FCF per Share | -1.18 | -0.73 | -1.53 | 0.13 | -1.49 | -0.39 | -0.51 |
| FCF Conversion (FCF/Net Income) | 1.36x | 0.78x | 0.96x | -0.13x | 0.68x | 0.58x | 0.89x |
| Interest Paid | -246K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 283K | 355K | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying LVTX stock.
LAVA Therapeutics N.V. (LVTX) generated $-19.5M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
LAVA Therapeutics N.V. (LVTX) reported negative free cash flow of $19.6M in 2024, indicating capital requirements exceeded cash from operations.
LAVA Therapeutics N.V. (LVTX) spent $0.0M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.